Ensysce Biosciences (ENSCW) Receivables - Net (2018 - 2025)

Ensysce Biosciences (ENSCW) has 7 years of Receivables - Net data on file, last reported at $7.4 million in Q4 2025.

• Receivables - Net for Q4 2025 came in at $7.4 million, up 362.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.4 million (up 362.5% YoY), and the FY2025 annual result was $7.4 million, up 362.5% from the prior year.
• Receivables - Net eased to $7.4 million in Q4 2025 per ENSCW's latest filing, from $8.9 million in the prior quarter.
• Over five years, Receivables - Net peaked at $10.7 million in Q2 2022 and troughed at $1.6 million in Q4 2024.
• A 5-year average of $6.4 million and a median of $8.2 million in 2025 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net plunged 85.05% in 2024, then surged 394.74% in 2025.
• A 5-year view of Receivables - Net shows it stood at $2.8 million in 2021, then jumped by 282.14% to $10.7 million in 2022, then changed by 0.0% to $10.7 million in 2023, then sank by 85.05% to $1.6 million in 2024, then surged by 362.5% to $7.4 million in 2025.
• Business Quant data shows ENSCW's Receivables - Net at $7.4 million in Q4 2025, $8.9 million in Q3 2025, and $9.4 million in Q2 2025.